baricitinib

This page shows the latest baricitinib news and features for those working in and with pharma, biotech and healthcare.

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)

Latest news

Gilead and Galapagos close in on filing for Xeljanz rival

If approved, filgotinib would likely be the fourth JAK inhibitor for RA after Pfizer’s $1.8bn seller Xeljanz (tofacitinib), Eli Lilly’s Olumiant (baricitinib), and AbbVie’s upadacitinib which has
New data keeps AbbVie’s star pipeline therapies on track

Lilly reported positive phase II results with its already-approved Olumiant (baricitinib) drug in the skin disorder at last year’s EADV, as did Pfizer with PF-04965842, a more selective
Gilead, Galapagos JAK inhibitor clears phase II test

DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in
GSK sells eczema and psoriasis drug to Dermavant for £250m

s Xeljanz (tofacitinib) and Incyte/Eli Lilly’s Olumiant (baricitinib).
Another R&D flop for Incyte, but Jakafi keeps delivering

Nevertheless, it’s another bit of bad news for Incyte after the epacadostat failure, what looks likely to be reduced royalties from Eli Lilly for rheumatoid arthritis JAK inhibitor Olumiant (baricitinib)

More from news
Approximately 9 fully matching, plus 28 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Graduate Scientific Editor: DOE

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Account Director, Medical Education: Salary TBC

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Account Executive: Salary TBC

Account Supervisor: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director: Salary TBC

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Subscribe to our email news alerts

PMHub

Add my company

Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Spotlight interview: 15 minutes on insights and market research in pharma: Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma...
WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment: Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game: Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....